Expressions of TRPC5 and miR-320a in thyroid cancer and their clinical significances_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 PANG Chang’an ¹ , ZHU Honghai ² , LI Xuejuan ¹ , LI Hongqiang ³

1. Department of Otorhinolaryngology, Head and Neck Surgery, Zhengzhou Seventh People’s Hospital, Zhengzhou 450006, P. R. China;
2. Department of Rhinology, The First Clinical Medical College of Zhengzhou University, Zhengzhou 450052, P. R. China;
3. Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P. R. China;

Corresponding?author：

PANG Chang’an, Email: panm8011@163.com

Keywords：

thyroid cancer; transient receptor potential channel C5; microRNA-320a; clinicopathologic features; prognosis

DOI：

10.7507/1007-9424.202011099

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To detect expressions of transient receptor potential channel C5 (TRPC5) and microRNA-320a (miR-320a) in thyroid cancer and explore clinical significances of them in thyroid cancer.Methods The expressions of TRPC5 and miR-320a mRNA in the thyroid cancer were investigated by searching the Ualcan database. While the expressions of TRPC5 and miR-320a mRNA in 80 cases of thyroid cancer, 35 cases of thyroid adenoma and 32 cases of normal thyroid tissues adjacent to thyroid adenoma tissues in the Zhengzhou Seventh People’s Hospital from March 2014 to March 2015 were tested. Real time PCR was used to detect the expressions of TRPC5 mRNA and miR-320a mRNA in the various tissues and Western blot was used to detect the TRPC5 protein in the thyroid cancer tissues. Therelationships between the expressions of TRPC5 and miR-320a mRNAs and clinicopathologic features of thyroid cancer were analyzed. The correlation between expressions of TRPC5 and miR-320a mRNA was analyzed by Pearson method. The risk factors influencing the prognosis were analyzed by univariate and multivariate Cox proportional hazards regression model.Results The results of Ualcan database showed that the expression level of TRPC5 mRNA in the thyroid cancer was higher than that in the normal thyroid tissue (P<0.001), while the expression level of miR-320a mRNA was lower than that in the normal thyroid tissue (P<0.001). The results of clinical cases showed that the expression level of TRPC5 mRNA was significantly higher, while the expression of miR-320a mRNA was significantly lower in the thyroid cancer tissues as compared with the normal thyroid tissues (P<0.05). There was a negative correlation between the expression level of TRPC5 and miR-320a mRNA in the thyroid cancer (r=?0.653, P<0.001). The expressions of TRPC5 and miR-320a mRNA were correlated with the degree of differentiation, lymph node metastasis, and TNM stage (P<0.05). Kaplan-Meier survival curve analysis found that the patients with higher expression level of TRPC5 and lower expression level of miR-320a showed the poor prognosis, and multivariate analysis found that the lower tumor differentiation, later TNM stage, with lymph node metastasis, higher expression level of TRPC5 mRNA, and lower expression level of miR-320a mRNA were the risk factors affecting prognostic survival (P<0.05).Conclusions From the database and clinical case data, it is concluded that TRPC5 mRNA is highly expressed, while miR-320a mRNA is lowly expressed in thyroid cancer tissues, and expressions of TRPC5 and miR-320a mRNA are related to degree of tumor differentiation, lymph node metastasis, TNM staging, and prognosis in patients with thyroid cancer. TRPC5 and miR-320a mRNA might be used as potential indicators for clinical and prognostic monitoring.

Citation： PANG Chang’an, ZHU Honghai, LI Xuejuan, LI Hongqiang. Expressions of TRPC5 and miR-320a in thyroid cancer and their clinical significances. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(9): 1165-1170. doi: 10.7507/1007-9424.202011099 Copy

1.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
2.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
3.	Ancker OV, Krüger M, Wehland MI, et al. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci, 2019, 21(1): 10.
4.	魏濤, 朱精強. p53 基因家族與甲狀腺癌的相關研究進展. 中國普外基礎與臨床雜志, 2019, 26(11): 1372-1377.
5.	延常姣, 黃美玲, 肖晶晶, 等. 甲狀腺癌相關多原發癌的臨床及病理特征分析. 現代腫瘤醫學, 2020, 28(1): 40-43.
6.	Tankeu AT, Ndip Agbor V, Noubiap JJ. Calcium supplementation and cardiovascular risk: A rising concern. J Clin Hypertens (Greenwich), 2017, 19(6): 640-646.
7.	傅倩云, 朱瑞宇, 方羅, 等. 下調 TRPC5 的表達對卵巢癌細胞耐藥性影響的研究. 中國細胞生物學學報, 2019, 41(4): 681-687.
8.	石少敏, 趙建軍, 于杜鵑, 等. miR-320a 靶向 Rab11a 調控非小細胞肺癌細胞增殖的研究. 中國實驗診斷學, 2018, 22(9): 1636-1638.
9.	程瑩星, 黃勇, 張麗娟, 等. 乳腺癌組織中 miR-320a 的表達及意義. 山東醫藥, 2018, 58(25): 20-22.
10.	李雨珊, 張仁靜, 周雪梅, 等. 微小 RNA-181a-5P、320a 及其靶基因 TGF-β1 在食管鱗癌中的表達. 腫瘤預防與治療, 2019, 32(5): 395-401.
11.	余長云, 李金映, 曹華. 基于數據挖掘分析 NETO2 基因在頭頸鱗癌中的表達及臨床意義. 現代腫瘤醫學, 2019, 27(18): 3223-3225.
12.	Yapa S, Mulla O, Green V, et al. The role of chemokines in thyroid carcinoma. Thyroid, 2017, 27(11): 1347-1359.
13.	Iglesias ML, Schmidt A, Ghuzlan AA, et al. Radiation exposure and thyroid cancer: a review. Arch Endocrinol Metab, 2017, 61(2): 180-187.
14.	Ren H, Shen Y, Hu D, et al. Co-existence of BRAF^V600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag Res, 2018, 10: 1005-1013.
15.	Lu JY, Cheng WC, Chen KY, et al. Using ion torrent sequencing to study genetic mutation profiles of fatal thyroid cancers. J Formos Med Assoc, 2018, 117(6): 488-496.
16.	張浩, 孫威. 長鏈非編碼 RNA 與甲狀腺癌發生發展關系的研究進展及其臨床價值. 中國普外基礎與臨床雜志, 2018, 25(10): 1161-1164.
17.	He DX, Ma X. Transient receptor potential channel C5 in cancer chemoresistance. Acta Pharmacol Sin, 2016, 37(1): 19-24.
18.	Chen Z, Zhu Y, Dong Y, et al. Overexpression of TrpC5 promotes tumor metastasis via the HIF-1α-Twist signaling pathway in colon cancer. Clin Sci (Lond), 2017, 131(19): 2439-2450.
19.	荀瑞峰, 魯厚根, 汪獻旺. CDC25C 在肝癌中的表達及其意義. 重慶醫學, 2020, 49(4): 633-637.
20.	劉歡, 李紅昌, 陳亞峰, 等. 微小 RNA 在三陰性乳腺癌中的研究進展. 中國普外基礎與臨床雜志, 2020, 27(1): 103-106.
21.	Xie F, Yuan Y, Xie L, et al. miRNA-320a inhibits tumor proliferation and invasion by targeting c-Myc in human hepatocellular carcinoma. Onco Targets Ther, 2017, 10: 885-894.
22.	Chen Z, Tang C, Zhu Y, et al. TrpC5 regulates differentiation through the Ca²⁺/Wnt5a signalling pathway in colorectal cancer. Clin Sci (Lond), 2017, 131(3): 227-237.
23.	劉亞群, 張秀瓏, 張志華, 等. miR-320a 與肺部惡性腫瘤相關性的研究進展. 河北北方學院學報(自然科學版), 2020, 36(2): 58-60.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
3. Ancker OV, Krüger M, Wehland MI, et al. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci, 2019, 21(1): 10.
4. 魏濤, 朱精強. p53 基因家族與甲狀腺癌的相關研究進展. 中國普外基礎與臨床雜志, 2019, 26(11): 1372-1377.
5. 延常姣, 黃美玲, 肖晶晶, 等. 甲狀腺癌相關多原發癌的臨床及病理特征分析. 現代腫瘤醫學, 2020, 28(1): 40-43.
6. Tankeu AT, Ndip Agbor V, Noubiap JJ. Calcium supplementation and cardiovascular risk: A rising concern. J Clin Hypertens (Greenwich), 2017, 19(6): 640-646.
7. 傅倩云, 朱瑞宇, 方羅, 等. 下調 TRPC5 的表達對卵巢癌細胞耐藥性影響的研究. 中國細胞生物學學報, 2019, 41(4): 681-687.
8. 石少敏, 趙建軍, 于杜鵑, 等. miR-320a 靶向 Rab11a 調控非小細胞肺癌細胞增殖的研究. 中國實驗診斷學, 2018, 22(9): 1636-1638.
9. 程瑩星, 黃勇, 張麗娟, 等. 乳腺癌組織中 miR-320a 的表達及意義. 山東醫藥, 2018, 58(25): 20-22.
10. 李雨珊, 張仁靜, 周雪梅, 等. 微小 RNA-181a-5P、320a 及其靶基因 TGF-β1 在食管鱗癌中的表達. 腫瘤預防與治療, 2019, 32(5): 395-401.
11. 余長云, 李金映, 曹華. 基于數據挖掘分析 NETO2 基因在頭頸鱗癌中的表達及臨床意義. 現代腫瘤醫學, 2019, 27(18): 3223-3225.
12. Yapa S, Mulla O, Green V, et al. The role of chemokines in thyroid carcinoma. Thyroid, 2017, 27(11): 1347-1359.
13. Iglesias ML, Schmidt A, Ghuzlan AA, et al. Radiation exposure and thyroid cancer: a review. Arch Endocrinol Metab, 2017, 61(2): 180-187.
14. Ren H, Shen Y, Hu D, et al. Co-existence of BRAF^V600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag Res, 2018, 10: 1005-1013.
15. Lu JY, Cheng WC, Chen KY, et al. Using ion torrent sequencing to study genetic mutation profiles of fatal thyroid cancers. J Formos Med Assoc, 2018, 117(6): 488-496.
16. 張浩, 孫威. 長鏈非編碼 RNA 與甲狀腺癌發生發展關系的研究進展及其臨床價值. 中國普外基礎與臨床雜志, 2018, 25(10): 1161-1164.
17. He DX, Ma X. Transient receptor potential channel C5 in cancer chemoresistance. Acta Pharmacol Sin, 2016, 37(1): 19-24.
18. Chen Z, Zhu Y, Dong Y, et al. Overexpression of TrpC5 promotes tumor metastasis via the HIF-1α-Twist signaling pathway in colon cancer. Clin Sci (Lond), 2017, 131(19): 2439-2450.
19. 荀瑞峰, 魯厚根, 汪獻旺. CDC25C 在肝癌中的表達及其意義. 重慶醫學, 2020, 49(4): 633-637.
20. 劉歡, 李紅昌, 陳亞峰, 等. 微小 RNA 在三陰性乳腺癌中的研究進展. 中國普外基礎與臨床雜志, 2020, 27(1): 103-106.
21. Xie F, Yuan Y, Xie L, et al. miRNA-320a inhibits tumor proliferation and invasion by targeting c-Myc in human hepatocellular carcinoma. Onco Targets Ther, 2017, 10: 885-894.
22. Chen Z, Tang C, Zhu Y, et al. TrpC5 regulates differentiation through the Ca²⁺/Wnt5a signalling pathway in colorectal cancer. Clin Sci (Lond), 2017, 131(3): 227-237.
23. 劉亞群, 張秀瓏, 張志華, 等. miR-320a 與肺部惡性腫瘤相關性的研究進展. 河北北方學院學報(自然科學版), 2020, 36(2): 58-60.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expressions of TRPC5 and miR-320a in thyroid cancer and their clinical significances

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content